Weight-loss drugs show signs of slowing biological aging, say drugmakers

Pharmaceutical giants Eli Lilly and Novo Nordisk have reported that their popular GLP-1 weight-loss drugs may offer benefits beyond weight management, potentially slowing biological aging. By utilizing molecular “aging clocks”—which measure DNA changes and protein levels—researchers observed that patients taking these medications experienced a reduction in biological age by approximately two to three years compared to those on a placebo. Experts suggest these findings position GLP-1 drugs as potential “geroprotectors,” medications capable of slowing or reversing biological aging processes. While the effects were most pronounced in unhealthy populations, the data provides significant validation for the utility of aging clocks as biomarkers. These studies, presented at the Aging Research & Drug Discovery conference, highlight the drugs' broader impact on health span, including improved kidney function and reduced mortality risk, marking a significant development in the quest for longevity treatments.